Study of Nifedipine GITS and Candesartan Combination Compared to Monotherapy in Patients With Essential Hypertension

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1381 participants.

Also called NCT01303783

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 1,381 participants (enrolled count) (from the registry)
Sponsor
  • Bayer Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01303783
  • EudraCT 2009-017077-37
Other papers using this trial's data
  • Nifedipine GITS/Candesartan Combination Therapy Lowers Blood Pressure Across Different Baseline Systolic and Diastolic Blood Pressure Categories: DISTINCT Study Subanalyses Journal of clinical pharmacology, 2016-09 DOI, PubMed 26829251, PMC5111757 In the PMC Open Access subset under CC BY-NC-ND.
  • Nifedipine plus candesartan combination increases blood pressure control regardless of race and improves the side effect profile: DISTINCT randomized trial results Journal of hypertension, 2014-12 DOI, PubMed 25144296, PMC4227617 In the PMC Open Access subset under CC BY-NC-ND.

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States, Argentina, Belgium, Brazil, Canada, Italy, Lithuania, Russia, South Africa, South Korea, Spain, Ukraine, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01303783. Randomized; quadruple masking; primary purpose treatment. Start 2011-04 (registry gives no type); primary completion 2012-05 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study of Nifedipine GITS and Candesartan Combination Compared to Monotherapy in Patients With Essential Hypertension
Acronym
DISTINCT
Condition
Hypertension, Essential
Intervention (Drug)
Candesartan cilexetil (Atacand), 4 mg
Intervention (Drug)
Candesartan cilexetil (Atacand), 8 mg
Intervention (Drug)
Nifedipine GITS (Adalat, BAYA1040), 20 mg
Intervention (Drug)
Nifedipine GITS (Adalat, BAYA1040), 30 mg
Intervention (Drug)
Nifedipine GITS (Adalat, BAYA1040), 60 mg
Intervention (Drug)
Placebo
Intervention (Drug)
Candesartan cilexetil (Atacand), 16 mg
Intervention (Drug)
Candesartan cilexetil (Atacand), 32 mg
Lead sponsor
Bayer (class: industry)

Record details

Record id
cardio:ct-nct01303783
Content hash
35c85d0502183ff0c043d80364b3f910b992b5ed72912e9df5d4696b1f73fdf0